The effectiveness of currently existing immune checkpoint inhibitors for treating KRAS mutation-containing pancreatic cancer is disappointing and indicates the need to explore additional pathways involved in immune evasion that should be targeted for therapy. Here, KRAS is linked to familial pancreatic carcinoma.